Hepatitis B Virus Genotypic Resistance to Lamivudine
Authors: Hélène Fontaine, Valérie Thiers, Stanislas Pol
Journal: Annals of Internal Medicine (1999)

Letters2 November 1999Hepatitis B Virus Genotypic Resistance to LamivudineHélène Fontaine, MD, Valérie Thiers, PhD, and Stanislas Pol, MD, PhDHélène Fontaine, MDHôpital Necker; 75015 Paris, France (Fontaine)Hôpital Necker; 75015 Paris, France (Thiers)Hôpital Necker; 75015 Paris, France (Pol)Search for more papers by this author, Valérie Thiers, PhDHôpital Necker; 75015 Paris, France (Fontaine)Hôpital Necker; 75015 Paris, France (Thiers)Hôpital Necker; 75015 Paris, France (Pol)Search for more papers by this author, and Stanislas Pol, MD, PhDHôpital Necker; 75015 Paris, France (Fontaine)Hôpital Necker; 75015 Paris, France (Thiers)Hôpital Necker; 75015 Paris, France (Pol)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-9-199911020-00027 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Lamivudine is a potent inhibitor of HIV reverse transcriptase and of hepatitis B virus (HBV) DNA polymerase (1). Its long-term efficacy in chronic HBV infection is limited by relapse after discontinuation and breakthrough during therapy by genotypic resistance. Hepatitis B virus breakthrough has been described in immunocompetent patients and patients who have received liver transplants. We report the first cases of HBV lamivudine resistance in HIV-infected patients.Nineteen patients with HIV and HBV were treated with lamivudine (300 mg/d) for a median of 16 months (range, 4 to 34 months). All patients were negative for hepatitis C ...References1. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, et al . Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med. 1996;125:705-12. LinkGoogle Scholar2. Ling R, Mutiner D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al . Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 1996;24:711-3. CrossrefMedlineGoogle Scholar3. Allen M, Deslauriers M, Andrews W, Tipples G, Walters K, Tyrell D, et al . Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology. 1998;27:1670-7. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Hélène Fontaine, MD; Valérie Thiers, PhD; Stanislas Pol, MD, PhDAffiliations: Hôpital Necker; 75015 Paris, France (Fontaine)Hôpital Necker; 75015 Paris, France (Thiers)Hôpital Necker; 75015 Paris, France (Pol) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDelayed Chain Termination Protects the Anti-hepatitis B Virus Drug Entecavir from Excision by HIV-1 Reverse TranscriptaseIdentification of a Ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapyClinically relevant sequence-based genotyping of HBV, HCV, CMV, and HIVVaccination of chronic hepatitis B virus carriers with preS2/S envelope protein is not associated with the emergence of envelope escape mutants 2 November 1999Volume 131, Issue 9 Page: 716-717 Keywords DNA Hepatitis B virus HIV Liver Liver transplantation Methionine Morbidity Patients Polymerases Viremia ePublished: 15 August 2000 Issue Published: 2 November 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...